What is the primary outcome of the Study on Evaluation of Candesartan Cilexetil after Renal Transplantation (SECRET)?
The primary outcome of the Study on Evaluation of Candesartan Cilexetil after Renal Transplantation (SECRET) was all-cause mortality, cardiovascular morbidity, or graft failure.